BC
CNTA

Brookfield Corp’s Centessa Pharmaceuticals CNTA Stock Holding History

Brookfield Corp’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,788
Closed -$447K – 646
2021
Q3 		$447K Buy
26,788
+8,384
+46% +$174K ﹤0.01% 477
2021
Q2 		$409K Buy
+18,404
New +$433K ﹤0.01% 510

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Brookfield Corp's CNTA Position: Q4 2021 in Review

Brookfield Corp sold out of Centessa Pharmaceuticals (CNTA) in Q4 2021, closing a stake of 26,788 shares — an estimated $447K sold.

Brookfield Corp first reported a position in CNTA in Q2 2021 and held it in 2 quarters. The position peaked at $447K in Q3 2021. 47 funds tracked by Wall St. Rank hold CNTA as of Q4 2021.

  • Brookfield Corp reported no remaining Centessa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Brookfield Corp sold 26,788 Centessa Pharmaceuticals shares in Q4 2021, an estimated $447K.
  • Brookfield Corp first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Brookfield Corp's Centessa Pharmaceuticals position peaked at $447K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2021.

Based on Brookfield Corp's 13F filing for Q4 2021, filed 14 Feb 2022.